Home › New Data Investigating Mercks KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015
 

Keywords :   


New Data Investigating Mercks KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015

2015-03-18 21:19:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Data to be Presented Across Multiple Tumor Types for KEYTRUDA and MK-8628 (OTX015), an Investigational BET-Bromodomain Inhibitor KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in both advanced non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma will be presented as part of the Clinical Trials Plenary Session on Sunday, April 19 at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, April 18 22. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data advanced presented cell

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
13.05Melinda French Gates to quit Gates Foundation
13.05BASF in South Carolina Joins with Make-A-Wish
13.05PCMC addresses latest printing trends at \'Power Packs Live\'
13.05More than 50 sessions scheduled for drupa cube
13.05IDENTCO highlights automation and PCB labeling at PCB East
13.05Piracy on social media and messaging apps grows in Asia Pacific
13.05Anoki launches AI-powered experience on Google TV
13.05INDA, AFS Partner on FiltXPO 2025 Conference Program
More »